A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants
Status:
Not yet recruiting
Trial end date:
2024-03-10
Target enrollment:
Participant gender:
Summary
The study tests if treatment with cagrilintide delays the transmission of electrical signals
in the heart compared to treatment with placebo. To confirm the sensitivity of the
methodology, the drug moxifloxacin is also compared to a placebo in 2 treatment arms.
Cagrilintide is being developed for the treatment of obesity and weight management.
Moxifloxacin is an approved antibiotic for the treatment of bacterial illnesses. The study
lasts for up to 17 weeks for each participant.
Phase:
Phase 1
Details
Lead Sponsor:
Novo Nordisk A/S
Treatments:
Moxifloxacin Norgestimate, ethinyl estradiol drug combination